We Manufacture Products That Change Lives™
Life changing perinatal tissue allografts based on our proprietary BioREtain® process.
Best-In-Class Perinatal Tissue Allografts
- BioStem Technologies® produces innovative perinatal tissue-based allografts.
- Our membrane allografts are manufactured using our proprietary BioRetain® processing method that preserves the quality of the tissue.
- In our AATB® accredited, FDA® registered, cGMP compliant lab, we strive to provide products and services that adhere to Current Good Tissue Practice requirements.
Best-In-Class Perinatal Tissue Allografts
- BioStem Technologies® produces innovative perinatal tissue-based allografts.
- Our membrane allografts are processed using our proprietary BioRetain® processing method that preserves the biologic quality of the tissue.
- In our AATB® accredited, FDA® registered, cGMP compliant lab, we strive to provide products and services that adhere to Current Good Tissue Practice requirements.
Why Choose Us
BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies.
Our allografts are processed utilizing our proprietary BioRetain® method, which focuses on preserving the tissue’s endogenous biological properties while maintaining the structure and matrix found in fresh perinatal tissue.
BioStem is committed to improving patients’ quality of life through scientific innovation and strict adherence to our quality system.
Latest News
-
BioStem Technologies Announces Notice of Allowance for Four U.S. Design Patent Applications Covering Fenestrated Human Placental Allografts and One European Patent
BioStem Technologies Expands Global Placental Allograft Patent Portfolio Pompano Beach, FL, May 20, 2026 (GLOBE NEWSWIRE) — BioStem Technologies®, a leading regenerative medicine company focused on developing and commercializing placental-derived biologics, today announced that the United States Patent and Trademark Office (USPTO) has issued Notices of Allowance for four new divisional U.S. design patent applications related to its fenestrated human placental allograft technologies. The European Patent Office also issued BioStem…
Subscribe to our Newsletter
To stay up to date on all of our news, products, and achievements, please subscribe to our newsletter.
